Breast cancer with high levels of human epidermal growth factor receptor type 2 (HER2) expression, which accounts for 15–20% of all cases, has been associated with increased tumor aggressiveness as well as a high risk of recurrence and death [38]. This evidence concerns the gene ERBB2 and neoplasm.